头孢地尔罗治疗成年和儿科囊性纤维化和木糖氧化无色杆菌感染患者。
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
机构信息
Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
Clinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
出版信息
Clin Infect Dis. 2021 Oct 5;73(7):e1754-e1757. doi: 10.1093/cid/ciaa1847.
Abstract
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
摘要
对于木糖氧化无色杆菌的治疗选择有限。8 例囊性纤维化患者接受了 12 个头孢地尔膦疗程的治疗。8 例中有 3 例在治疗前体外耐药。12 个疗程中有 11 个疗程出现临床应答。然而，在 12 个疗程中有 11 个疗程观察到微生物学复发，值得注意的是没有出现耐药性。
相似文献
1
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.头孢地尔罗治疗成年和儿科囊性纤维化和木糖氧化无色杆菌感染患者。
Clin Infect Dis. 2021 Oct 5;73(7):e1754-e1757. doi: 10.1093/cid/ciaa1847.
2
Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.一名成年囊性纤维化患者发生严重木糖氧化无色杆菌感染及痰液细菌多样性丧失
Paediatr Respir Rev. 2016 Aug;20 Suppl:27-9. doi: 10.1016/j.prrv.2016.06.011. Epub 2016 Jun 15.
3
Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.囊性纤维化患者中泛耐药木糖氧化无色杆菌和嗜麦芽窄食单胞菌感染不会降低肺移植后的生存率。
Transplantation. 2015 Oct;99(10):2196-202. doi: 10.1097/TP.0000000000000709.
4
Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid.马德里一家成人囊性纤维化治疗中心的木糖氧化无色杆菌感染
Enferm Infecc Microbiol Clin. 2016 Mar;34(3):184-7. doi: 10.1016/j.eimc.2015.05.006. Epub 2015 Jun 29.
5
JMM Profile: : the cloak-and-dagger opportunist.JMM 档案：神秘莫测的机会主义者。
J Med Microbiol. 2022 May;71(5). doi: 10.1099/jmm.0.001505.
6
Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.联合噬菌体与头孢地尔、美罗培南/比阿培南治疗小儿囊性纤维化患者泛耐药不动杆菌属感染。
Pediatr Pulmonol. 2020 Nov;55(11):2990-2994. doi: 10.1002/ppul.24945. Epub 2020 Jul 20.
7
Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease.一名患有囊性纤维化和严重肺部疾病的儿童由木糖氧化无色杆菌引起的脓毒症
Am J Case Rep. 2016 Aug 8;17:562-6. doi: 10.12659/ajcr.896577.
8
Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.噬菌体疗法治疗囊性纤维化患者木糖氧化无色杆菌肺部感染：一例报告
Res Microbiol. 2018 Nov;169(9):540-542. doi: 10.1016/j.resmic.2018.05.001. Epub 2018 May 16.
9
A Case of Phage Therapy against Pandrug-Resistant in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient.噬菌体治疗对 12 岁肺移植囊性纤维化患者泛耐药 的一例报告。
Viruses. 2021 Jan 5;13(1):60. doi: 10.3390/v13010060.
10
Achromobacter xylosoxidans induced bronchiolitis obliterans in cystic fibrosis.木糖氧化无色杆菌在囊性纤维化中诱发闭塞性细支气管炎。
Pediatr Pulmonol. 2014 Apr;49(4):414-6. doi: 10.1002/ppul.22864. Epub 2013 Aug 23.
引用本文的文献
1
Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study.头孢地尔治疗嗜麦芽窄食单胞菌、洋葱伯克霍尔德菌复合体和无色杆菌属感染患者：来自珀尔修斯研究的亚组分析
Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1367-1374. doi: 10.1007/s10096-025-05109-5. Epub 2025 Mar 24.
2
Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol.使用头孢地尔成功治疗一名患有嗜麦芽窄食单胞菌医院获得性肺炎的新生儿。
Infection. 2025 Jun;53(3):1227-1231. doi: 10.1007/s15010-024-02404-9. Epub 2024 Oct 7.
3
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.头孢地尔治疗产VIM型革兰阴性菌感染
Antibiotics (Basel). 2024 Sep 12;13(9):874. doi: 10.3390/antibiotics13090874.
4
Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study.在PEDI-CEFI 2期研究中，单剂量或多剂量头孢地尔在接受标准治疗抗生素治疗感染的3个月至未满18岁住院儿科患者中的药代动力学、安全性和耐受性。
Pediatr Infect Dis J. 2025 Feb 1;44(2):136-142. doi: 10.1097/INF.0000000000004529. Epub 2024 Sep 4.
5
Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus.市售的用于检测头孢地尔罗酯药敏性的检测方法在不动杆菌属中表现出不同的性能。
Ann Clin Microbiol Antimicrob. 2024 Aug 22;23(1):78. doi: 10.1186/s12941-024-00731-1.
6
Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.嗜麦芽窄食单胞菌属对头孢地尔罗的药敏性：对 230 株准确鉴定的菌株的研究。
Ann Clin Microbiol Antimicrob. 2024 Jun 17;23(1):54. doi: 10.1186/s12941-024-00709-z.
7
Performance evaluation of Bruker UMIC microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species.布鲁克UMIC 微量稀释板和纸片扩散法评估头孢地尔罗在肠杆菌科、鲍曼不动杆菌、铜绿假单胞菌、嗜麦芽寡养单胞菌、木糖氧化无色杆菌和伯克霍尔德菌属中的药敏性能。
Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):559-566. doi: 10.1007/s10096-024-04745-7. Epub 2024 Jan 19.
8
and activity of cefiderocol against spp. and complex, including carbapenem-non-susceptible isolates.以及头孢地尔在治疗 spp. 和 复杂感染（包括耐碳青霉烯类的分离株）方面的活性。
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0034623. doi: 10.1128/aac.00346-23. Epub 2023 Nov 16.
9
An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.头孢地尔的治疗潜力及潜在耐药机制概述
Life (Basel). 2023 Jun 21;13(7):1427. doi: 10.3390/life13071427.
10
New Antimicrobials for the Treatment of Neonatal Sepsis Caused by Multi-Drug-Resistant Bacteria: A Systematic Review.用于治疗多重耐药菌引起的新生儿败血症的新型抗菌药物：一项系统评价
Antibiotics (Basel). 2023 May 24;12(6):956. doi: 10.3390/antibiotics12060956.
本文引用的文献
1
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.头孢地尔与大剂量延长输注美罗培南治疗革兰阴性菌医院获得性肺炎（APEKS-NP）：一项随机、双盲、3期、非劣效性试验。
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
2
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
3
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.头孢地尔在 ICU 患者治疗鲍曼不动杆菌和其他碳青霉烯类耐药革兰氏阴性菌感染中的应用。
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.
4
Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.联合噬菌体与头孢地尔、美罗培南/比阿培南治疗小儿囊性纤维化患者泛耐药不动杆菌属感染。
Pediatr Pulmonol. 2020 Nov;55(11):2990-2994. doi: 10.1002/ppul.24945. Epub 2020 Jul 20.
5
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.头孢地尔罗与对照药物对癌症患者分离株的活性。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01955-19.
6
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects.健康成年受试者中新型铁载体头孢菌素头孢地尔的肺部药代动力学。
J Antimicrob Chemother. 2019 Jul 1;74(7):1971-1974. doi: 10.1093/jac/dkz123.
7
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
8
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.头孢地尔优于亚胺培南西司他丁钠治疗革兰氏阴性尿路病原体引起的复杂性尿路感染：一项 2 期、随机、双盲、非劣效性试验。
Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.
9
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.2015-2016 年北美和欧洲临床实验室分离的革兰氏阴性杆菌的体外药敏试验：SIDERO-WT-2015。
Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.
10
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
Zotero 插件